Sign in Subscribe
Pediatrics

Rapid Clearance of Lu-177-DOTATATE in Children with Neuroblastoma

Strategic Insights

— 2 min read

A study published in Clinical Nuclear Medicine has evaluated the clearance of Lu-177-DOTATATE in pediatric patients with neuroblastoma, assessing the effective doses received by patients, family caregivers, and medical staff during therapy. The research enrolled 23 children aged 3-13 years who received Lu-177-DOTATATE between 2023 and 2024. The study found that the compound was rapidly cleared in children with neuroblastoma, with a mean administered activity of 3.687 +/- 1.545 GBq and whole-body retention rates ranging from 72.0% to 10.0% at 1-96 hours post-administration.

Key Takeaways:

  • Lu-177-DOTATATE was rapidly cleared in children with neuroblastoma, with a biexponential decay model indicating estimated effective half-lives of 1.4 +/- 0.8 and 52.3 +/- 18.6 hours.
  • The maximum cumulative effective doses (within 11 days) at 1 and 2 meters were 0.442 +/- 0.174 and 0.138 +/- 0.058 mSv, respectively.
  • Radiopharmacists received an average of 3.7 +/- 1.8 mu Sv/patient, while nurses received an average of 16.7 (10, 470) mu Sv/patient in terms of whole-body and finger-effective doses.
  • Radiation exposure to others was below personal dose limits, with absorbed doses for children being 0.159 +/- 0.076 mGy/MBq (whole body) and 0.611 +/- 0.416 mGy/MBq (red-marrow).
  • Financial supporters for this research include the National Natural Science Foundation of China (NSFC) and the Natural Science Foundation of Shandong Province.
  • This research has significant implications for the optimization of Lu-177-DOTATATE therapy in pediatric patients with neuroblastoma.

Statistics:

  • Mean administered activity: 3.687 +/- 1.545 GBq
  • Whole-body retention rates at 1-96 hours post-administration: 72.0% to 10.0%
  • Estimated effective half-lives: 1.4 +/- 0.8 and 52.3 +/- 18.6 hours
  • Maximum cumulative effective doses at 1 and 2 meters: 0.442 +/- 0.174 and 0.138 +/- 0.058 mSv, respectively
  • Average finger-effective dose for radiopharmacists: 155.3 +/- 73.0 mu Sv/patient
  • Average whole-body and finger-effective doses for nurses: 4.7 +/- 1.4 mu Sv/patient and 16.7 (10, 470) mu Sv/patient, respectively

Sources:

  • NewsRx. Studies from Shandong Cancer Hospital and Institute Yield New Data on Neuroblastomas (Radiation Exposure To Patients and Others During Therapy for Pediatric Neuroblastoma With Lu-177-dotatate). Health & Medicine Week. June 13, 2025; p 614.
  • Radiation Exposure To Patients and Others During Therapy for Pediatric Neuroblastoma With Lu-177-dotatate. Clinical Nuclear Medicine, 2025;50(6):480-485.

Read more